Growth Metrics

NovoCure (NVCR) Gross Profit (2016 - 2025)

NovoCure's Gross Profit history spans 11 years, with the latest figure at $132.2 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 3.44% year-over-year to $132.2 million; the TTM value through Dec 2025 reached $488.5 million, up 4.37%, while the annual FY2025 figure was $488.5 million, 4.37% up from the prior year.
  • Gross Profit for Q4 2025 was $132.2 million at NovoCure, up from $122.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $132.2 million in Q4 2025 and bottomed at $92.0 million in Q2 2023.
  • The 5-year median for Gross Profit is $106.6 million (2021), against an average of $109.0 million.
  • The largest annual shift saw Gross Profit soared 40.06% in 2021 before it dropped 18.09% in 2023.
  • A 5-year view of Gross Profit shows it stood at $103.5 million in 2021, then dropped by 3.85% to $99.5 million in 2022, then rose by 1.69% to $101.2 million in 2023, then grew by 26.25% to $127.8 million in 2024, then grew by 3.44% to $132.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Gross Profit are $132.2 million (Q4 2025), $122.5 million (Q3 2025), and $117.3 million (Q2 2025).